Treatment of hepatitis delta virus genotype 3 infection with peg-interferon and entecavir | Zendy

Lourdes Maria Pinheiro Borzacov | Zendy; Larissa Deadame de Figueiredo Nicolete | Zendy; Luan Felipo Botelho Souza | Zendy; Alcione Oliveira dos Santos | Zendy; Deusilene Souza Vieira | Zendy; Juan Miguel Villalobos Salcêdo | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Treatment of hepatitis delta virus genotype 3 infection with peg-interferon and entecavir

Author(s) -

Lourdes Maria Pinheiro Borzacov,

Larissa Deadame de Figueiredo Nicolete,

Luan Felipo Botelho Souza,

Alcione Oliveira dos Santos,

Deusilene Souza Vieira,

Juan Miguel Villalobos Salcêdo

Publication year - 2016

Publication title -

international journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.278

H-Index - 89

eISSN - 1878-3511

pISSN - 1201-9712

DOI - 10.1016/j.ijid.2016.03.017

Subject(s) - entecavir , hepatitis d virus , medicine , virology , hepatitis d , genotype , pegylated interferon , virus , hepatitis b virus , viral load , gastroenterology , immunology , hepatitis c virus , ribavirin , biology , hbsag , gene , biochemistry , lamivudine

Hepatitis delta virus (HDV) is recognized as the most pathogenic and infectious among the hepatotropic viruses. Studies on the treatment of HDV have predominantly included European patients and carriers of genotype 1 (HDV-1) in their clinical protocols. For the Amazon region, data show that infected individuals have mainly Native American ancestry and that >90% of HDV carriers have the genotype 3 (HDV-3). Thus combined therapy clinical protocols do not adequately address the treatment of these patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research